Dexamethasone first drug to improve survival in COVID-19

16 June 2020

The cheap generic steroid dexamethasone reduces death by up to one third in hospitalized patients with severe respiratory complications of COVID-19, according to a University of Oxford study.

In March 2020, the RECOVERY study was established as a randomized clinical trial to test a range of potential treatments for COVID-19, including low-dose dexamethasone. In excess of 11,500 patients have been enrolled from more than 175 hospitals in the UK.

A total of 2,104 patients were randomized to receive dexamethasone 6mg once per day, either by mouth or by intravenous injection, for 10 days and were compared with 4,321 patients randomized to usual care alone.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK